Immucell (ICCC) Receivables (2010 - 2026)

Immucell (ICCC) has reported Receivables for 17 consecutive years, with $2.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 19.8% year-over-year to $2.9 million; the trailing twelve-month figure through Jun 2026 stood at $2.9 million (up 19.8% YoY), and the FY2025 full-year result was $3.5 million, down 9.48% from the prior year.
• Receivables grew to $2.9 million in Q2 2026 per ICCC's latest filing, from $31177.0 in the prior quarter.
• Across five years, Receivables topped out at $7.8 million in Q1 2022 and bottomed at $31177.0 in Q4 2025.
• Historically, Receivables has averaged $3.1 million across 5 years, with a median of $2.4 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Receivables soared 213.01% in 2022, then tumbled 95.43% in 2023.
• Over 5 years, Receivables stood at $1.8 million in 2022, then sank by 95.43% to $82240.0 in 2023, then increased by 12.66% to $92652.0 in 2024, then tumbled by 66.35% to $31177.0 in 2025, then jumped by 9213.39% to $2.9 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $2.9 million, $31177.0, and $2.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.